Needham analyst David Saxon downgrades Globus Medical (NYSE:GMED) from Buy to Hold.
INOVIO Announces Acceptance Of Abstract For Oral Presentation On INO-4201 As An Ebola Booster For rVSV-ZEBOV At ECCMID 2023
Immunological data from recently completed Phase 1b trial will be presented on April 16th
PLYMOUTH MEETING, Pa., April 12, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company